79 related articles for article (PubMed ID: 28917835)
1. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
Park H; Kim D; Son E; Shin S; Sa JK; Kim SH; Yoon Y; Nam DH
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):409-415. PubMed ID: 28917835
[TBL] [Abstract][Full Text] [Related]
2. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
Park H; Kim D; Kim E; Sa JK; Lee HW; Yu S; Oh J; Kim SH; Yoon Y; Nam DH
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902178
[TBL] [Abstract][Full Text] [Related]
3. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
4. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma.
Hwang DW; Bahng N; Ito K; Ha S; Kim MY; Lee E; Suga H; Lee DS
Cancer Lett; 2017 Jan; 385():144-149. PubMed ID: 27810404
[TBL] [Abstract][Full Text] [Related]
6. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
9. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
10. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
11. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
[TBL] [Abstract][Full Text] [Related]
12. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
Han JM; Myung H; Kim S
Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
[TBL] [Abstract][Full Text] [Related]
14. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
15. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
[TBL] [Abstract][Full Text] [Related]
16. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
Michaud NR; Jani JP; Hillerman S; Tsaparikos KE; Barbacci-Tobin EG; Knauth E; Putz H; Campbell M; Karam GA; Chrunyk B; Gebhard DF; Green LL; Xu JJ; Dunn MC; Coskran TM; Lapointe JM; Cohen BD; Coleman KG; Bedian V; Vincent P; Kajiji S; Steyn SJ; Borzillo GV; Los G
MAbs; 2012; 4(6):710-23. PubMed ID: 23007574
[TBL] [Abstract][Full Text] [Related]
18. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
20. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
Zhang HT; Wang L; Ai J; Chen Y; He CX; Ji YC; Huang M; Yang JY; Zhang A; Ding J; Geng MY
J Pharmacol Exp Ther; 2014 Jul; 350(1):36-45. PubMed ID: 24741075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
